New hepatitis c drug safety checked in patients with organ damage
NCT ID NCT06911320
First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 28 times
Summary
This early-stage study looks at how a single dose of the experimental hepatitis C drug combination bemnifosbuvir/ruzasvir behaves in people with severe kidney or liver impairment compared to healthy volunteers. About 28 adults will take one dose and be monitored for safety and drug levels. The goal is to understand if organ problems affect how the drug is processed, not to treat the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL IMPAIRMENT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Atea Study Site
RECRUITINGOrlando, Florida, 32809, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Atea Study Site
RECRUITINGTampa, Florida, 33603, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.